Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith

Abstract

Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9H-purin-2-ylamino]-cyclohexan-1-ol, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed.

1 . A crystal form comprising the compound of the formula: 
       
         
           
           
               
               
           
         
       
       which has an X-ray powder diffraction pattern comprising peaks at 12.4, 16.0, 18.5 and 24.1 °2θ±0.1 when measured using Cu Kα radiation. 
     
     
         2 . The crystal of  claim 1  which has a differential scanning calorimetry thermogram having an endotherm with an onset temperature of approximately 225° C. 
     
     
         3 . The crystal form of  claim 2  which has a thermogravimetric analysis thermogram having a total mass loss of less than 1% of the total mass of the sample when heated from about 25° C. to about 200° C. 
     
     
         4 . The crystal form of  claim 1  which comprises less than 2% by weight of other crystal forms. 
     
     
         5 . The crystal form of  claim 1  further comprising peaks at 17.7 and 23.2 °2θ±0.1 when measured using Cu Kα radiation. 
     
     
         6 . The crystal form of  claim 5  further comprising one or more additional peaks at 10.0, 12.8, 15.2, 16.3, 18.9, 19.4, 20.0, 20.6, 20.9, 21.6, 22.7, 26.1, 26.6, 26.8, 25.7, 26.0, 26.4, 26.6, 27.2, 27.9, 30.2, 30.8, 31.0, 31.5 °2θ±0.1 when measured using Cu Kα radiation. 
     
     
         7 . A pharmaceutical composition comprising a crystal form of  claim 1  and a pharmaceutically acceptable diluent, excipient or carrier. 
     
     
         8 . The pharmaceutical composition of  claim 7  suitable for oral, parenteral, mucosal, transdermal or topical administration. 
     
     
         9 . A single unit dosage form comprising a crystal form of  claim 1 , and a pharmaceutically acceptable carrier, excipient or diluent. 
     
     
         10 . The single unit dosage form of  claim 9  suitable for oral, parenteral, mucosal, transdermal or topical administration. 
     
     
         11 . The crystal form of  claim 1  which has a thermogravimetric analysis thermogram having a total mass loss of approximately 1% of the total mass of the sample when heated from about 25° C. to about 200° C. 
     
     
         12 . The crystal form of  claim 1  which comprises about 2% by weight of other crystal forms. 
     
     
         13 . A solid form which has an X-ray powder diffraction pattern comprising peaks at approximately 12.4, 16.0 and 18.5 °2θ, prepared by a process comprising evaporating a solution comprising the compound of formula (I): 
       
         
           
           
               
               
           
         
       
       or a salt thereof, in a solvent selected from the group consisting of acetone, n-butanol, ethanol, methanol, 2-propanol, tetrahydrofuran, ethanol/water (1/1) and mixtures thereof. 
     
     
         14 . The solid form of  claim 13  which is crystalline. 
     
     
         15 . A solid form which has an X-ray powder diffraction pattern comprising peaks at approximately 12.4, 16.0 and 18.5 °2θ, prepared by a process comprising slurrying a solution comprising the compound of formula (I): 
       
         
           
           
               
               
           
         
       
       or a salt thereof, in a solvent selected from the group consisting of acetone, acetonitrile, n-butanol, ethanol, ethyl acetate, heptane, methylene chloride, methyl ethyl ketone, methyl t-butyl ether, 2-propanol, toluene, water, ethanol/water (1/1) and mixtures thereof. 
     
     
         16 . The solid form of  claim 15  which is crystalline. 
     
     
         17 . A solid form which has an X-ray powder diffraction pattern comprising peaks at approximately 12.4, 16.0 and 18.5 °2θ, prepared by a process comprising solvent/antisolvent precipitation of a solution comprising the compound of formula (I): 
       
         
           
           
               
               
           
         
       
       or a salt thereof, wherein the solvent/antisolvent system is selected from the group consisting of ethanol/water, ethanol/methyl t-butyl ether, ethanol/heptane, tetrahydrofuran/methyl t-butyl ether, tetrahydrofuran/heptane and tetrahydrofuran/toluene. 
     
     
         18 . The solid form of  claim 17  which is crystalline.